Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Mugsy ,

<< Previous

Bullboard Posts

Next >>

Comment by Doccoleon Jul 18, 2021 1:07pm

156 Views

Post# 33566904

RE:Mugsy ,

He would cheer and say "in my opinion" "buying opportunity" "great job in buying more" "lots of positive catalysts" "Marky private message me and I'll explain what a dividend is."

I am just busting balls. I do appreciate both the positive and negative ends of the spectrum.

anyways we are all in it to win it. Some of us are cynical, some delusional, some borderline insane. I think this stock has made us this way. I blame the stock swings!

hopefully ATE started the AME trial and we will have results eoy

<< Previous

Bullboard Posts

Next >>

Victory Battery Metals acquires Utah and Saskatchewan uranium projects